XML 84 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment and Geographic Information
6 Months Ended 12 Months Ended
Jun. 30, 2012
Dec. 31, 2011
Segment Reporting [Abstract]    
Segment and Geographic Information
Segment Information

The Centaur Companies are engaged in the rental and sale of advanced wound care systems, regenerative medicine products and therapeutic support systems. The Centaur Companies have operations in more than 20 countries.

The Centaur Companies have three reportable operating segments which correspond to our three global business units: AHS, TSS and LifeCell. Our three global operating segments also represent our reporting units as defined by the Codification. In most countries where we operate, our product lines are marketed and serviced by the same infrastructure and, as such, we have allocated these costs to the various business units based on allocation methods including rental and sales events, headcount, revenue and other methods as deemed appropriate. We measure segment profit (loss) as operating earnings (loss), which is defined as income (loss) before interest and other income, interest expense, foreign currency gains and losses, and income taxes. All intercompany transactions are eliminated in computing revenue and operating earnings (loss).

Information on segments and a reconciliation of consolidated totals are as follows (dollars in thousands):

 
Three months ended June 30,
 
Six months ended June 30,
 
2012
 
2011
 
2012
 
2011
 
Successor
 
Predecessor
 
Successor
 
Predecessor
Revenue:
 
 
 
 
 
 
 
   AHS
$
330,318

 
$
356,940

 
$
656,506

 
$
696,504

   TSS
56,944

 
65,523

 
115,434

 
133,150

   LifeCell
107,797

 
96,330

 
214,142

 
189,344

             Total revenue
$
495,059

 
$
518,793

 
$
986,082

 
$
1,018,998


 
Three months ended June 30,
 
Six months ended June 30,
 
2012
 
2011
 
2012
 
2011
 
Successor
 
Predecessor
 
Successor
 
Predecessor
Operating earnings (loss):
 
 
 
 
 
 
 
   AHS (1)
$
104,308

 
$
128,815

 
$
175,746

 
$
243,189

   TSS (1)
(5,927
)
 
4,387

 
(21,453
)
 
8,619

   LifeCell (1)
23,575

 
24,775

 
46,639

 
52,913

   Non-allocated costs:
 
 
 
 
 
 
 
      General headquarter expense
(9,081
)
 
(8,606
)
 
(14,027
)
 
(22,688
)
      Equity-based compensation
(492
)
 
(8,234
)
 
(989
)
 
(15,879
)
      Merger-related and other expenses (2)
(31,313
)
 
(3,644
)
 
(42,065
)
 
(5,238
)
      Acquired intangible asset amortization (3)
(54,325
)
 
(8,856
)
 
(123,750
)
 
(17,712
)
         Total non-allocated costs
(95,211
)
 
(29,340
)
 
(180,831
)
 
(61,517
)
             Total operating earnings (loss)
$
26,745

 
$
128,637

 
$
20,101

 
$
243,204

________________________________
(1)
The three months ended June 30, 2012 includes the allocation of depreciation expense and cost of sales associated with the preliminary purchase accounting adjustments related to the step up in value of rental medical equipment (“RME”) and inventory of $29.9 million, $7.7 million and $8.3 million, respectively, to our AHS, TSS and LifeCell operating segments. The six months ended June 30, 2012 includes the allocation of depreciation expense and cost of sales associated with the preliminary purchase accounting adjustments related to the step up in value of RME and inventory of $62.4 million, $23.0 million and $16.9 million, respectively, to our AHS, TSS and LifeCell operating segments. In addition, our AHS operating segment includes a $12.4 million impairment charge during the first quarter 2012 associated with certain production equipment at our AHS manufacturing plant.
(2)
The three and six months ended ended June 30, 2012 includes expenses related to the Merger for seller transaction costs, management fees and restructuring-related expenses as well as business optimization expenses. In addition, the three and six months ended ended June 30, 2012 and 2011 includes expenses related to our global business transformation efforts.
(3)
The three and six months ended ended June 30, 2011 includes amortization of acquired intangible assets related to our purchase of LifeCell in May 2008.
Segment and Geographic Information

The Centaur Companies are engaged in the rental and sale of advanced wound care systems, regenerative medicine products and therapeutic support systems. The Centaur Companies have operations in more than 20 countries.

The Centaur Companies have three reportable operating segments which correspond to our three global business units: AHS; TSS; and LifeCell. Our three global operating segments also represent our reporting units as defined by the Codification. In most countries where we operate, our product lines are marketed and serviced by the same infrastructure and, as such, we have allocated these costs to the various business units based on allocation methods including rental and sales events, headcount, revenue and other methods as deemed appropriate. We measure segment profit (loss) as operating earnings (loss), which is defined as income (loss) before interest and other income, interest expense, foreign currency gains and losses, and income taxes. All intercompany transactions are eliminated in computing revenue and operating earnings (loss).

Information on segments and a reconciliation of consolidated totals are as follows (dollars in thousands):
 
Period from
November 4
through
December 31, 2011
 
Period from
January 1
through
November 3, 2011
 
Year Ended December 31,
 
 
 
2010
 
2009
 
Successor
 
Predecessor
 
Predecessor
 
Predecessor
Revenue:
 
 
 
 
 
 
 
AHS
$
231,147

 
$
1,181,944

 
$
1,402,035

 
$
1,402,417

TSS
42,494

 
214,727

 
270,154

 
300,171

LifeCell
73,615

 
321,451

 
341,405

 
285,898

Total revenue
$
347,256

 
$
1,718,122

 
$
2,013,594

 
$
1,988,486

 
 
 
 
 
 
 
 
Operating earnings (loss):
 
 
 
 
 
 
 
AHS
$
72,830

 
$
440,383

 
$
463,252

 
$
444,296

TSS
899

 
8,764

 
9,561
 (1)
 
36,387

LifeCell
13,029

 
89,178

 
93,948

 
80,251

Non-allocated costs:
 
 
 
 
 
 
 
General headquarter expense
(3,948
)
 
(46,837
)
 
(49,312
)
 
(43,153
)
Equity-based compensation (2)
(306
)
 
(81,354
)
 
(32,781
)
 
(32,506
)
Merger-related expenses (3)
(148,713
)
 
(46,619
)
 

 

LifeCell acquisition-related expenses (4)

 
(29,519
)
 
(38,293
)
 
(42,791
)
Total non-allocated costs
(152,967
)
 
(204,329
)
 
(120,386
)
 
(118,450
)
Total operating earnings (loss)
$
(66,209
)
 
$
333,996

 
$
446,375

 
$
442,484

_____________________________
(1)
Includes $7.4 million of expenses associated with the TSS product portfolio rationalization recorded in the second quarter of 2010.
(2)
Includes $55.0 million related to the acceleration of equity-based compensation expense due to immediate vesting upon the Merger.
(3)
Represents expenses related to the Merger including buyer and seller transaction costs, management fees, restructuring-related expenses and amortization of acquired intangible assets.
(4)
Includes amortization of acquired intangible assets and costs to retain key employees related to our purchase of LifeCell in May 2008.

 
Period from
November 4
through
December 31, 2011
 
Period from
January 1
through
November 3, 2011
 
Year Ended December 31,
 
 
 
2010
 
2009
 
Successor
 
Predecessor
 
Predecessor
 
Predecessor
Depreciation and other amortization:
 
 
 
 
 
 
 
AHS
$
44,238

 
$
55,568

 
$
72,474

 
$
62,668

TSS
4,021

 
18,343

 
27,691

 
34,014

LifeCell
8,670

 
44,667

 
57,370

 
60,248

Other
(178
)
 
(892
)
 
(1,070
)
 
(1,070
)
 
$
56,751

 
$
117,686

 
$
156,465

 
$
155,860



Significant non-cash expense other than depreciation and amortization expense includes the Merger-related periodic recognition of cost of sales associated with the application of preliminary purchase accounting adjustments to step up the value of inventory. For the period from November 4 through December 31, 2011, we recognized $2.1 million, $5.3 million and $0.4 million, respectively, in related cost of sales for our AHS, TSS and LifeCell business units.

AHS, TSS and LifeCell assets are primarily accounts receivable, inventories, goodwill, intangible assets and net property, plant and equipment generally identifiable by product. Other assets include assets not specifically identifiable to a product, such as cash, deferred income taxes, prepaid expenses, net debt issuance costs and other non-current assets. Information on segment assets are as follows (dollars in thousands):
 
December 31,
 
2011
 
2010
 
2009
 
Successor
 
Predecessor
 
Predecessor
Total assets:
 
 
 
 
 
AHS
$
4,977,917

 
$
764,619

 
$
779,464

TSS
192,227

 
181,851

 
192,535

LifeCell
2,328,671

 
1,704,337

 
1,712,376

Other
422,564

 
425,192

 
354,190

 
$
7,921,379

 
$
3,075,999

 
$
3,038,565




AHS, TSS and LifeCell gross capital expenditures primarily relate to manufactured rental assets, manufacturing equipment, and computer hardware and software identifiable by product. Other capital expenditures include those not specifically identifiable to a product, such as the purchase of land and the construction of our global headquarters building, leasehold improvements, and computer hardware and software. The following table contains information on gross capital expenditures (dollars in thousands):

 
Period from
November 4
through
December 31, 2011
 
Period from
January 1
through
November 3, 2011
 
Year Ended December 31,
 
 
 
2010
 
2009
 
Successor
 
Predecessor
 
Predecessor
 
Predecessor
Gross capital expenditures:
 
 
 
 
 
 
 
AHS
$
10,080

 
$
5,842

 
$
10,212

 
$
17,140

TSS
6,614

 
7,905

 
10,994

 
15,047

LifeCell
7,047

 
10,832

 
10,099

 
9,113

Other
12,267

 
73,977

 
54,578

 
61,989

 
$
36,008

 
$
98,556

 
$
85,883

 
$
103,289



Other selected geographic financial information is presented separately for the successor and predecessor periods. In the successor presentation, the Bailiwick of Guernsey represents the domestic location and in the predecessor presentation, the United States represents the domestic location. Revenues are attributed to countries based on the location of our entity providing the products or services. Information on the geographical location of select financial information is as follows (dollars in thousands):

 
Period from
November 4
through
December 31, 2011
 
 
Successor
Geographic location of revenue:
 
Domestic
$

United States
257,008

Other foreign
90,248

Total revenue
$
347,256

 
Period from
January 1
through
November 3, 2011
 
Year Ended December 31,
 
 
2010
 
2009
 
Predecessor
 
Predecessor
 
Predecessor
Geographic location of revenue:
 
 
 
 
 
Domestic
$
1,266,532

 
$
1,503,451

 
$
1,471,956

Foreign
451,590

 
510,143

 
516,530

Total revenue
$
1,718,122

 
$
2,013,594

 
$
1,988,486


 
December 31,
2011
 
Successor
Geographic location of long-lived assets (1):
 
Domestic
$

United States
360,365

Other foreign
184,982

Total long-lived assets
$
545,347

_____________________________
(1)
Long-lived assets exclude intangible assets.
 
December 31,
 
2010
 
2009
 
Predecessor
 
Predecessor
Geographic location of long-lived assets (1):
 
 
 
Domestic
$
184,131

 
$
198,211

Foreign
86,932

 
97,844

Total long-lived assets
$
271,063

 
$
296,055

_____________________________
(1)
Long-lived assets exclude intangible assets.